Company:Neuropathix
 | |
| Type | Public |
|---|---|
| Expert Market: NPTX | |
| Industry | Pharmaceutical Biotechnology |
| Founders | Dean Petkanas, Thoma Kikis |
| Headquarters | Doylestown, Pennsylvania |
| Total assets | Patents US patent 9611213, US patent 10004722 |
| Website | neuropathix.com |
Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics.[1]
In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019[2][3][4] along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol.[5] Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders.
In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH).[6] The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain.[7]
Neuropathix is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE.[8]
References
- ↑ Rees, Victoria (November 26, 2020). "Cannabinoid series: a CBD-inspired molecule to increase bioavailability". European Pharmaceutical Review. https://www.europeanpharmaceuticalreview.com/article/133860/cannabinoid-series-a-cbd-inspired-molecule-to-increase-bioavailability/?_r=0. Retrieved 2020-11-26.
- ↑ "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Medicinal Chemistry Letters 7 (4): 424–8. April 2016. doi:10.1021/acsmedchemlett.6b00009. PMID 27096053.
- ↑ "Pharmacological Comparisons Between Cannabidiol and KLS-13019". Journal of Molecular Neuroscience 66 (1): 121–134. September 2018. doi:10.1007/s12031-018-1154-7. PMID 30109468.
- ↑ "Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity". Journal of Molecular Neuroscience 68 (4): 603–619. August 2019. doi:10.1007/s12031-019-01321-z. PMID 31077084.
- ↑ "Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS‐13019 in mouse models of pain and reinforcement". British Journal of Pharmacology 178 (15): 3067–3078. April 2021. doi:10.1111/bph.15486. PMID 33822373.
- ↑ "Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)" (in en). https://finance.yahoo.com/news/neuropathix-inc-wholly-owned-subsidiary-130000546.html.
- ↑ "Development of KLS-13019 for Neuropathic Pain" (in en). https://reporter.nih.gov/project-details/10326595.
- ↑ Baskin, Ben (July 12, 2016). "How cannabis is helping one company research treatment of CTE". Sports Illustrated. http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife. Retrieved 2016-07-12.
External links
 |  |
